Previously, data demonstrated that BCL2 and BCR-ABL1 kinase dual inhibition eradicates CML stem cells derived from patients in blast crisis [19]. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.